in force 2009-01-20 MODIFIED+43 −8§
Amended by Regulation (EC) No 1272/2008 32008R1272
applies from: unchanged
Sources disagree — the text comparison and the EU's own amendment metadata found this change; the amending act's instructions do not mention it. All are shown; none is overruled.
The list of purposes for dossiers in the introduction now describes the identification item as covering CMRs, PBTs, vPvBs, or a substance of equivalent concern in accordance with Article 59, whereas the earlier version described this item as covering PBTs, vPvBs, or a substance of equivalent concern without mentioning CMRs or Article 59 there.
The remainder of the Annex, including the content-of-dossiers section, is unchanged in substance between the two versions.
Cited: Annex XV, v1 · Annex XV, v2
text before / after
02006R1907-20081012 → 02006R1907-20090120
ANNEX XV
DOSSIERS
I. INTRODUCTION AND GENERAL PROVISIONS
This Annex lays down general principles for preparing dossiers to propose and justify:
harmonised classification and labelling of CMRs, respiratory sensitisers and other effects,
the identification of CMRs, PBTs, vPvBs, or a substance of equivalent concern, concern in accordance with Article 59,
restrictions of the manufacture, placing on the market or use of a substance within the Community.
The relevant parts of Annex I shall be used for the methodology and format of any dossier according to this Annex.
For all dossiers any relevant … 571 unchanged words … compared to its net costs to manufacturers, importers, downstream users, distributors, consumers and society as a whole.
Information on stakeholder consultation
Information on any consultation of stakeholders and how their views have been taken into account shall be included in the dossier.